Avanos Medical, Inc. cash flow to debt ratio of 57.86% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Avanos Medical, Inc.'s free cash flow has decreased -48.01% from $82.90M last year to $43.10M, signaling decreasing performance

Avanos Medical, Inc.'s debt to equity ratio is 0.18, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Avanos Medical, Inc.'s debt has decreased relative to shareholder equity from 0.21 last year to 0.18 today, signaling strengthened financials

Avanos Medical, Inc. has negative EBITDA, making leverage ratio unreliable

Avanos Medical, Inc.'s interest coverage ratio is -7.88, which means that the company struggles to meet interest obligations, signaling financial risk.

Avanos Medical, Inc.'s profit margin has increased (-83.00%) in the last year from -57.01% to -9.69%, signaling increasing performance

Avanos Medical, Inc.'s short-term assets of $355.40M exceed its short-term liabilities of $165.20M

Avanos Medical, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Avanos Medical, Inc.'s return on equity of -8.91%, is lower than 15.00%, indicating bad performance

Avanos Medical, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Avanos Medical, Inc. had positive net income in only 2.00 out of 5 years, indicating unstable earnings

Avanos Medical, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Avanos Medical, Inc. has a free cash flow yield of 3.69%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Avanos Medical, Inc.'s yearly earnings has increased -82.68% since last year from $-392.10M to $-67.90M, signaling increasing performance

Avanos Medical, Inc.'s yearly revenue has increased 1.95% since last year from $687.80M to $701.20M, signaling increasing performance

ROIC -6.03% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Avanos Medical, Inc.'s 3-year revenue CAGR of 0.83% is positive, indicating growing revenue over the past 3 years

Avanos Medical, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Avanos Medical, Inc. had positive ROE in only 2.00 out of 5 years, indicating inconsistent returns on equity

Avanos Medical, Inc. has insufficient data to evaluate this check.

Avanos Medical, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Avanos Medical, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Avanos Medical, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Avanos Medical, Inc. is overvalued relative to its fair value price of 7.70 based on Earnings Fair Value model

Avanos Medical, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Avanos Medical, Inc. has a price-to-book ratio of 1.48x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Avanos Medical, Inc. has a price-to-sales ratio of 1.62x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue